Invention Grant
- Patent Title: Azabenzimidazole derivatives
-
Application No.: US15543242Application Date: 2016-01-13
-
Publication No.: US10053471B2Publication Date: 2018-08-21
- Inventor: Frank Himmelsbach , Elke Langkopf
- Applicant: Boehringer Ingelheim International GmbH
- Applicant Address: DE Ingelheim am Rhein
- Assignee: Boehringer Ingelheim International GmbH
- Current Assignee: Boehringer Ingelheim International GmbH
- Current Assignee Address: DE Ingelheim am Rhein
- Agent Paula K. Wittmayer; David L. Kershner
- Priority: EP15151419 20150116; EP15167116 20150511
- International Application: PCT/EP2016/050557 WO 20160113
- International Announcement: WO2016/113299 WO 20160721
- Main IPC: C07D401/14
- IPC: C07D401/14 ; A61K31/437 ; C07D519/00 ; A61K45/06

Abstract:
The present invention relates to compounds of general formula (I), wherein R1, R2, R3, A1, A2, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
Public/Granted literature
- US20180002349A1 New Azabenzimidazole Derivatives Public/Granted day:2018-01-04
Information query